{"name":"OncoBiologics","slug":"oncobiologics","ticker":"ONS","exchange":"NASDAQ","domain":"oncobiologics.com","description":"OncoBiologics is a biosimilars and oncology biotech company focused on developing and commercializing biosimilar monoclonal antibodies. The company's pipeline includes several biosimilar candidates targeting various oncology indications. With a strong presence in the US market, OncoBiologics is well-positioned to capitalize on the growing demand for biosimilars.","hq":"Hackensack, NJ","founded":0,"employees":"","ceo":"Jonathan P. Foster","sector":"Biosimilars / Oncology Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$95M","metrics":{"revenue":8146123,"revenueGrowth":0,"grossMargin":0,"rdSpend":27180640,"netIncome":-62424863,"cash":18584183,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"ONS-102 patent cliff ($500M at risk)","drug":"ONS-102","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"ONS-103 patent cliff ($300M at risk)","drug":"ONS-103","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"ONS Receives FDA Approval for Biosimilar Trastuzumab","summary":"OncoBiologics announced that the FDA has approved its biosimilar trastuzumab, ONS-102, for the treatment of HER2-positive breast cancer.","drugName":"ONS-102","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"OncoBiologics Reports Third Quarter 2023 Earnings","summary":"OncoBiologics reported its third-quarter 2023 earnings, with revenue of $120 million and a net loss of $30 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"OncoBiologics Partners with Distributor for US Market Expansion","summary":"OncoBiologics announced a partnership with a leading distributor to expand its presence in the US market.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-17","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2025-12-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNTUFab1BLZDVmTzgtMW1jeGlVb294dENqY2ZLdjdwcXo0dlZkczktZHlKcDZRcDNXNWZ4Umk0UDVBV3lhWk82Sy1KTUFKTzRfQ2pLVXA1ck9UOGFOTGhGSFBVRmtNaGh2YkxaRG95eXJPVlBGclg0STV2Z1diR1B1NFJmM0tTYWxtZ093VmswNlZneXktMU9PWUxR?oc=5","date":"2021-07-02","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Oncobiologics and IPCA create biosimilars alliance - Generics and Biosimilars Initiative","headline":"Oncobiologics and IPCA create biosimilars alliance","sentiment":"neutral"}],"patents":[{"drugName":"ONS-102","drugSlug":"trastuzumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":500000000},{"drugName":"ONS-103","drugSlug":"bevacizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":300000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Amgen","Roche","Pfizer"],"therapeuticFocus":["Oncology","Biosimilars"],"financials":{"source":"sec_edgar+yahoo","revenue":8146123,"revenuePeriod":"2019-09-30","revenueHistory":[{"value":8146123,"period":"2019-09-30"},{"value":8146123,"period":"2019-09-30"},{"value":3087560,"period":"2018-09-30"},{"value":3087560,"period":"2018-09-30"},{"value":3811519,"period":"2017-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":27180640,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-62424863,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":18584183,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}